As I wrote in my previous post this morning, I like the upward momentum in the biotech sector resulting from the race for a coronavirus vaccine and treatment and the cash flows into the sector from investors and big drug companies such as Pfizer (PFE.) That has pushed the iShares NASDAQ Biotechnology ETF (IBB) up […]
To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the site. And we'll throw in the first week free! If you change your mind during that first week, just cancel your subscription from your profile page, and you won't be billed anything.